Concepedia

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Rebecca Ellston, Anna D. Staniszewska, Nicky Whalley, Sanjay K. Pandey, Mitchell Revill, Claire Rooney, Linda K. Buckett,

Science Translational Medicine · 2017 · 182 citations · 40 references

DOI

Concepts

Abstract

AZD4785 is a therapeutic antisense oligonucleotide targeting KRAS mRNA with promising preclinical antitumor activity and a favorable safety profile.

References

40

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text

, , +14

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi et al. · Nature · 2010 · 2.5K citations · Full text

, , +12

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

Haoqiang Ying, Alec C. Kimmelman, Costas A. Lyssiotis et al. · Cell · 2012 · 2K citations · Full text

, , +11

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

Jaekyoung Son, Costas A. Lyssiotis, Haoqiang Ying et al. · Nature · 2013 · 2K citations · Full text

, , +12

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

Erwei Song, Pengcheng Zhu, Sang‐Kyung Lee et al. · Nature Biotechnology · 2005 · 1K citations

, , +14